Authors : Sitbon O1, Cottin V2, Canuet M3, Clerson P4, Gressin V5, Perchenet L5, Bertoletti L6,7, Bouvaist H8, Picard F9, Prévot G10, Bergot E11, Simonneau G12.
EXTRACT:
Initial combination therapy plays a central role in managing pulmonary arterial hypertension (PAH) [1–4]. Patients with low- or intermediate-risk of 1-year mortality at diagnosis should be treated with initial combinaton therapy with an endothelin receptor antagonist (ERA) and phosphodiesterase type-5 inhibitor (PDE5i) [2–4]. Benefits of initial therapy with the ERA ambrisentan and PDE5i tadalafil were demonstrated in AMBITION [1]; prospective evidence for other treatment combinations within these drug classes is needed.